Cometriq

pharmadog

Sign In Subscribe

Cometriq · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 14, 2026

38 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (46)

Jul 9, 2033formulationUS 9724342
Jul 9, 2033formulationUS 9724342
Jul 9, 2033formulationUS 9724342
Feb 10, 2032formulationUS 11298349
Feb 10, 2032formulationUS 11298349
Feb 10, 2032formulationUS 11298349
Feb 10, 2032formulationUS 11298349
Feb 10, 2032formulationUS 11298349
Feb 10, 2032formulationUS 12128039
Feb 10, 2032formulationUS 12128039
Feb 10, 2032formulationUS 12128039
Feb 10, 2032formulationUS 12128039
Feb 10, 2032formulationUS 12128039
Feb 10, 2032formulationUS 9717720
Feb 10, 2032formulationUS 9717720
Jul 18, 2031method-of-use (U-2488)US 10034873
Jul 18, 2031method-of-use (U-2488)US 10034873
Jul 18, 2031method-of-use (U-2488)US 10034873
Jul 18, 2031method-of-use (U-1480)US 10039757
Jul 18, 2031method-of-use (U-1480)US 10039757
Jul 18, 2031method-of-use (U-1480)US 10039757
Oct 8, 2030compositionUS 88777764.3y
Oct 8, 2030compositionUS 88777764.3y
Oct 8, 2030compositionUS 88777764.3y
Oct 8, 2030compositionUS 88777764.3y
Oct 8, 2030compositionUS 88777764.3y
Jan 15, 2030compositionUS 110914393.5y
Jan 15, 2030compositionUS 110914393.5y
Jan 15, 2030compositionUS 110914393.5y
Jan 15, 2030compositionUS 110914393.5y
Jan 15, 2030compositionUS 110914393.5y
Jan 15, 2030formulationUS 110914403.5y
Jan 15, 2030formulationUS 110914403.5y
Jan 15, 2030formulationUS 110914403.5y
Jan 15, 2030formulationUS 110914403.5y
Jan 15, 2030formulationUS 110914403.5y
Jan 15, 2030method-of-use (U-1617)US 110980153.5y
Jan 15, 2030method-of-use (U-1617)US 110980153.5y
Jan 15, 2030method-of-use (U-3225)US 110980153.5y
Jan 15, 2030method-of-use (U-3225)US 110980153.5y
Jan 15, 2030method-of-use (U-3225)US 110980153.5y
Aug 14, 2026compositionUS 757947338d
Aug 14, 2026compositionUS 757947338d
Aug 14, 2026compositionUS 757947338d
Aug 14, 2026compositionUS 757947338d
Aug 14, 2026compositionUS 757947338d

FDA exclusivities (6)

Sep 17, 2028ODE-375Orphan Drug (7y)2.2y
Sep 17, 2028ODE-375Orphan Drug (7y)2.2y
Sep 17, 2028ODE-375Orphan Drug (7y)2.2y
Jan 14, 2026ODE-227Orphan Drug (7y)
Jan 14, 2026ODE-227Orphan Drug (7y)
Jan 14, 2026ODE-227Orphan Drug (7y)

cabozantinib s-malate

targets

all catalysts(25)

News(0)

comments(0)

Report a data issue

Patent cliff

patents (46)

FDA exclusivities (6)

🐶 often sniffed alongside

Trials studying cabozantinib s-malate